Infection and Adverse Outcomes in People With Chronic Heart Failure

2021 ◽  
Vol 78 (7) ◽  
pp. 760
Author(s):  
Michael Drozd ◽  
Richard M. Cubbon
2021 ◽  
Vol 1 (223) ◽  
pp. 2-14
Author(s):  
Gulmira Alipova ◽  
◽  
Anna Bazarova ◽  
Nazira Bazarova ◽  
Rimma Bazarbekova ◽  
...  

The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.


ESC CardioMed ◽  
2018 ◽  
pp. 2663-2665
Author(s):  
Rodrigo Modolo ◽  
Ana Paula de Faria

Hypertension and chronic heart failure are clinical conditions that greatly impact perioperative adverse outcomes of patients undergoing non-cardiac surgery. Although the first does not have a major impact on morbidity and mortality, it is the most frequent condition present in these patients. The second—chronic heart failure—is increasing in prevalence, with the ageing of the population and with the identification of incipient structural cardiac abnormalities, and has a major impact on the perioperative morbidity and mortality. For those reasons, the proper identification of these conditions in the perioperative setting is imperative in order to diminish perioperative adverse events. This chapter summarizes the current indications for identification, assessment of heart function and of cardiac markers, and the therapeutic management of these patients.


2017 ◽  
Vol 19 (6) ◽  
pp. 748-755 ◽  
Author(s):  
Muhammad Hammadah ◽  
Andreas P. Kalogeropoulos ◽  
Vasiliki V. Georgiopoulou ◽  
Malory Weber ◽  
Yuping Wu ◽  
...  

2011 ◽  
Vol 58 (4) ◽  
pp. 386-394 ◽  
Author(s):  
Bonnie Ky ◽  
Benjamin French ◽  
Kosha Ruparel ◽  
Nancy K. Sweitzer ◽  
James C. Fang ◽  
...  

2019 ◽  
pp. 28-33
Author(s):  
E. V. Filippov ◽  
K. A. Moseychuk

Coronary artery disease (CAD) can manifest as a classic chest pain, or atypical angina. At the same time, the prevalence of CAD in a group of male patients with atypical angina over the age of 60 can reach 59--78%. It should be noted that the clinic manifestation of the chronic heart failure (CHF), which will be the main limiting factor, may take centre stage in diffuse coronary artery atherosclerosis. In patients with coronary artery disease and heart failure, who take atorvastatin, one should expect a decrease in the risk of adverse outcomes and hospitalizations due to heart failure. However, this does not negate the need for treatment and optimization of heart failure, if necessary. The therapy of these patients is based on the administration of high doses of angiotensin converting enzyme inhibitors (ACE inhibitors), beta-blockers (BB) and statins. The routine use of statins in heart failure with low ejection fraction (EF) is not recommended for the management of patients with heart failure from clinical guidelines point of view. This conclusion is based on two multicenter randomized clinical trials that have purposefully studied the use of statins in heart failure (CORONA and GISSI-HF). However, this document recommends the use of statins to prevent heart failure in patients with coronary artery disease. Continuing statin therapy in patients, who are already receiving these drugs for coronary artery disease or hyperlipidemia, should also be discussed. Thus, the use of atorvastatin in patients with coronary artery disease and systolic left ventricular myocardial dysfunction can reduce the risk of adverse outcomes and hospitalizations due to heart failure. In patients with non-ischemic heart failure, taking statins is not associated with improved survival. Thus, the decision to prescribe this group of drugs in patients with chronic heart failure should take into account the specific clinical situation and be strictly individualized.


2009 ◽  
Vol 15 (6) ◽  
pp. S9
Author(s):  
Bonnie Ky ◽  
Stephen E. Kimmel ◽  
Radwan N. Safa ◽  
Mary E. Putt ◽  
Nancy K. Sweitzer ◽  
...  

2016 ◽  
Vol 22 (4) ◽  
pp. 256-262 ◽  
Author(s):  
Benjamin French ◽  
Le Wang ◽  
Bonnie Ky ◽  
Jeffrey Brandimarto ◽  
Anupam Basuray ◽  
...  

2007 ◽  
Vol 72 (4) ◽  
pp. 569-574 ◽  
Author(s):  
Koichi Setsuta ◽  
Yoshihiko Seino ◽  
Yasuyuki Kitahara ◽  
Masato Arau ◽  
Taminori Ohbayashi ◽  
...  

2021 ◽  
Vol 10 (3) ◽  
pp. 65-71
Author(s):  
S. L. Glizer ◽  
O. A. Shtegman ◽  
M. M. Petrova

Abstract. Chronic heart failure is one of the main contributors to the Global Burden of Cardiovascular Diseases. Despite advances in modern treatment, acute decompensated heart failure (ADHF) incidence is high. Moreover, patients admitted for ADHF encounter renal impairment, which is another predictor of adverse outcome. There are number of biomarkers that allow clinicians to assess the prognosis of the disease in the early stages. The article presents an overview of contemporary biomarkers (utilizing multimarker approach), and identifies the most significant biological markers for evaluating ADHF and worsening renal function.


Sign in / Sign up

Export Citation Format

Share Document